🎉 M&A multiples are live!
Check it out!

Xenon Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Xenon Pharmaceuticals and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Xenon Pharmaceuticals Overview

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.


Founded

1996

HQ

United States of America
Employees

327

Financials

LTM Revenue $0.6M

LTM EBITDA -$296M

EV

$1.9B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Xenon Pharmaceuticals Financials

Xenon Pharmaceuticals has a last 12-month revenue of $0.6M and a last 12-month EBITDA of -$296M.

In the most recent fiscal year, Xenon Pharmaceuticals achieved revenue of n/a and an EBITDA of -$277M.

Xenon Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Xenon Pharmaceuticals valuation multiples based on analyst estimates

Xenon Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$211M -$277M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$125M -$182M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Xenon Pharmaceuticals Stock Performance

As of April 15, 2025, Xenon Pharmaceuticals's stock price is $33.

Xenon Pharmaceuticals has current market cap of $2.6B, and EV of $1.9B.

See Xenon Pharmaceuticals trading valuation data

Xenon Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.9B $2.6B XXX XXX XXX XXX $-3.31

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Xenon Pharmaceuticals Valuation Multiples

As of April 15, 2025, Xenon Pharmaceuticals has market cap of $2.6B and EV of $1.9B.

Xenon Pharmaceuticals's trades at 3042.1x LTM EV/Revenue multiple, and -6.6x LTM EBITDA.

Analysts estimate Xenon Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Xenon Pharmaceuticals and 10K+ public comps

Xenon Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.9B XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -7.0x XXX XXX XXX
P/E -10.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -10.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Xenon Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Xenon Pharmaceuticals Valuation Multiples

Xenon Pharmaceuticals's NTM/LTM revenue growth is 1452%

Xenon Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Xenon Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Xenon Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Xenon Pharmaceuticals and other 10K+ public comps

Xenon Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 31% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Xenon Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Xenon Pharmaceuticals M&A and Investment Activity

Xenon Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Xenon Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Xenon Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Xenon Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Xenon Pharmaceuticals

When was Xenon Pharmaceuticals founded? Xenon Pharmaceuticals was founded in 1996.
Where is Xenon Pharmaceuticals headquartered? Xenon Pharmaceuticals is headquartered in United States of America.
How many employees does Xenon Pharmaceuticals have? As of today, Xenon Pharmaceuticals has 327 employees.
Who is the CEO of Xenon Pharmaceuticals? Xenon Pharmaceuticals's CEO is Mr. Ian C. Mortimer.
Is Xenon Pharmaceuticals publicy listed? Yes, Xenon Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Xenon Pharmaceuticals? Xenon Pharmaceuticals trades under XENE ticker.
When did Xenon Pharmaceuticals go public? Xenon Pharmaceuticals went public in 2014.
Who are competitors of Xenon Pharmaceuticals? Similar companies to Xenon Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Xenon Pharmaceuticals? Xenon Pharmaceuticals's current market cap is $2.6B
What is the current revenue of Xenon Pharmaceuticals? Xenon Pharmaceuticals's last 12-month revenue is $0.6M.
What is the current EBITDA of Xenon Pharmaceuticals? Xenon Pharmaceuticals's last 12-month EBITDA is -$296M.
What is the current EV/Revenue multiple of Xenon Pharmaceuticals? Current revenue multiple of Xenon Pharmaceuticals is 3042.1x.
What is the current EV/EBITDA multiple of Xenon Pharmaceuticals? Current EBITDA multiple of Xenon Pharmaceuticals is -6.6x.
Is Xenon Pharmaceuticals profitable? Yes, Xenon Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.